What issues should companies consider when implementing best practices for utilizing AI in the workplace? This resource outlines issues to consider when developing a corporate AI policy.
This sample policy establishes guidelines for the use of Artificial Intelligence tools.
The recent story of two New York attorneys “duped” by ChatGPT into citing “fake” cases in a court submission illustrates some of the risks of using artificial intelligence.
But the attorney missteps in the ChatGPT case are entirely avoidable. And the emergence of generative AI carries extraordinary potential if attorneys can learn to use the technology wisely.
This article discusses the Cyberspace Administration of China's (“CAC”) May 30, 2023 release of the long-awaited “Guidelines for the Filing of Standard Contracts Regarding Export of Personal Information (First Edition).
The guidelines provide clarity for organizations that are looking to rely on Standard Contractual Clauses (SCCs) to transfer personal information collected in Mainland China (“PRC Data”) to an offshore recipient.
This article examines, from an English law perspective, the legal issues you need to be familiar with whether you are engaged in data scraping (either directly or through a third party), or if you are concerned that your content is being scraped and exploited without your consent.
This article discusses China's new regulation on generative artificial intelligence. The new regulations are coming into light in the midst of new generative AI tools being introduced by several major Chinese technology providers.
This also marks China as one of the first countries globally that has direct government oversight over this nascent area of technology.
This sample invention disclosure form can be completed by scientists/inventors/creators to explain the item or technology they have developed. This form can be used to help determine whether an invention is sufficiently unique to be patented.
Canada is an attractive market for pharmaceutical manufacturers. Most Canadian consumers have some form of drug coverage through government programs and/or private insurance. Below are ten patent and regulatory topics that in-house counsel need to know before bringing an innovative product to Canada.
Editor's note: This article was updated to reflect recent developments; the original version of this article was published on December 16, 2020.
The September 2017 amendments to the Patented Medicines (Notice of Compliance) Regulations introduced a new scheme for pharmaceutical patent linkage litigation in Canada. That scheme is now much closer to the United States' (US) Hatch-Waxman scheme, but with remaining key differences that are explained in this chart.
Amendments to the Canadian Patent Act and enactment of the Certificate of Supplementary Protection Regulations flowing from the Canada-European Union (EU) Comprehensive Economic and Trade Agreement introduced a new framework in Canada for the issuance of Certificates of Supplementary Protection (CSPs).
This chart compare key aspects of the two regimes, Canada's and the EU's.